B

Baroness Meyer (Con)

Speaking in the House of Lords on 22 October 2026

Debate

Puberty Blockers and Cross-sex Hormones

Contribution

I thank the noble Baroness, Lady Deech, for tabling this important debate that concerns children and the age at which those trials should be undertaken. How can an 11 year-old child understand the consequences of interrupting their puberty, particularly when adults still lack reliable evidence about the long-term consequences? As we know, the Cass review concluded that the evidence supporting puberty blockers was sorely lacking and recommended their use only within a formal clinical trial. NHS England subsequently ended their routine use. As the noble Lord, Lord Frost, mentioned, in February, the PATHWAYS trial was paused following serious concern from the MHRA, including its recommendation that eligibility should be restricted to those aged 14 and over. Yet the revised protocol permits children as young as 11 to receive puberty blockers. Can the Minister explain what new evidence justified lowering the minimum age from 14 to 11 and 12 and what independent scrutiny preceded that decision? It is particularly troubling to note that the original committee reportedly met only three times, with just three members attending its final meeting. The need for better evidence cannot in itself justify exposing children to treatments, the long-term effects of which are uncertain and may be irreversible. Rather than using children as guinea pigs, should we not first examine the existing evidence of those who regretted their treatment, including Keira Bell and Sinead Watson? Eleven year-old girls and 12 year-old boys are barely out of primary school. We recognise that their capacity to assess long-term consequences is still developing. Under-18s cannot purchase alcohol or marry, even with parental consent. I am also concerned about children in care and those with autism or other mental difficulties. Yet children in care are eligible for the trial. Who will independently represent their interests? Children under 16 cannot give legal consent to participate in this medical trial; a parent or legal representative must consent on their behalf. But parents faced with a desperately unhappy child may feel enormous pressure to act. How will the trial ensure that consent is genuinely informed and each child’s understanding is properly assessed? Has recruitment begun? Will every participant receive thorough psychological assessment and continuing support? Above all, how do the Government reconcile the participation of children so young with their duty to protect them from harm? Is there not a danger that the state’s pursuit of scientific research is taking precedence over its duty to protect children? Are we really prepared to place 220 children in a trial without being able to answer the most basic question: at what age can a child understand and consent to a medical intervention that may shape the rest of their life? It was mentioned that children participate in clinical trials, but these are often children who have cancer, where the question of consent is quite different from participating in an experiment. I therefore ask the Minister directly: why 11 and 12 year-olds? What evidence justifies those ages, and how can the Government be confident that these children are being protected rather than exposed to risks that they are too young to understand? Their welfare must come first—not simply during the trial but throughout their childhood and their adult life.

More from Baroness Meyer (Con)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.